Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Consolidated Net Income (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Consolidated Net Income for 4 consecutive years, with -$34.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Consolidated Net Income fell 10.24% to -$34.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$25.6 million, a 80.29% increase, with the full-year FY2024 number at -$125.7 million, up 8.03% from a year prior.
  • Consolidated Net Income was -$34.4 million for Q3 2025 at Century Therapeutics, down from -$32.5 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $76.6 million in Q1 2025 to a low of -$39.4 million in Q4 2023.
  • A 4-year average of -$25.6 million and a median of -$31.7 million in 2022 define the central range for Consolidated Net Income.
  • Peak YoY movement for Consolidated Net Income: decreased 24.37% in 2023, then soared 372.82% in 2025.
  • Century Therapeutics' Consolidated Net Income stood at -$31.7 million in 2022, then dropped by 24.37% to -$39.4 million in 2023, then increased by 10.65% to -$35.2 million in 2024, then rose by 2.22% to -$34.4 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Consolidated Net Income are -$34.4 million (Q3 2025), -$32.5 million (Q2 2025), and $76.6 million (Q1 2025).